Calcium ascorbate and Hospitalisation - a phase IV clinical study of FDA data

Summary:

Hospitalisation is reported as a side effect among people who take Calcium ascorbate (vitamin c (ascorbic acid)), especially for people who are female, 50-59 old, also take Prednisone, and have Rheumatoid arthritis.

The phase IV clinical study analyzes which people have Hospitalisation when taking Calcium ascorbate. It is created by eHealthMe based on reports of 1,009 people who have side effects when taking Calcium ascorbate from the FDA, and is updated regularly.

What is Calcium ascorbate?

Calcium ascorbate has active ingredients of vitamin c (ascorbic acid). eHealthMe is studying from 1,018 Calcium ascorbate users. Check the latest studies of Calcium ascorbate.

What is Hospitalisation?

Hospitalisation is found to be associated with 1,713 drugs and 1,135 conditions by eHealthMe. Check the latest studies of Hospitalisation.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

1,009 people reported to have side effects when taking Calcium ascorbate.
Among them, 20 people (1.98%) have Hospitalisation.

Could Calcium ascorbate cause Hospitalisation?

Among these 20 people:

What is the gender of people who have Hospitalisation when taking Calcium ascorbate? *

female: 90 %
male: 10 %

What is the age of people who have Hospitalisation when taking Calcium ascorbate? *

What are other drugs people take besides Calcium ascorbate? *

What are other side effects people have besides Hospitalisation? *

Adverse Event: 17 people, 85.00%
Fibromyalgia (a long-term condition which causes pain all over the body): 15 people, 75.00%
Sleep Disorder: 13 people, 65.00%
Dyspnea (difficult or laboured breathing): 12 people, 60.00%
Headache (pain in head): 11 people, 55.00%
High Blood Pressure: 11 people, 55.00%
Asthma: 11 people, 55.00%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 11 people, 55.00%
Wheezing (a high-pitched whistling sound made while you breath): 10 people, 50.00%
Sensitisation (the state of being sensitive): 8 people, 40.00%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 9 people, 45.00%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 7 people, 35.00%
Psoriasis (immune-mediated disease that affects the skin): 5 people, 25.00%
Migraine (headache): 5 people, 25.00%
Asthma: 4 people, 20.00%
Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 1 person, 5.00%
Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 1 person, 5.00%
Indigestion: 1 person, 5.00%
Drowsiness: 1 person, 5.00%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 1 person, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Calcium ascorbate and have Hospitalisation?

- Check whether Hospitalisation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Calcium ascorbate:

Calcium ascorbate (1,018 reports)

Hospitalisation treatments and more:

Hospitalisation (143,651 reports)

Browse all side effects of Calcium ascorbate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hospitalisation:

Hospitalisation (1,713 drugs)

Browse all the conditions that are associated with Hospitalisation:

Hospitalisation (1,135 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on vitamin c (ascorbic acid) (the active ingredients of Calcium ascorbate) and Calcium ascorbate (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.